[go: up one dir, main page]

MX2025005209A - Compuestos lipídicos y usos de los mismos - Google Patents

Compuestos lipídicos y usos de los mismos

Info

Publication number
MX2025005209A
MX2025005209A MX2025005209A MX2025005209A MX2025005209A MX 2025005209 A MX2025005209 A MX 2025005209A MX 2025005209 A MX2025005209 A MX 2025005209A MX 2025005209 A MX2025005209 A MX 2025005209A MX 2025005209 A MX2025005209 A MX 2025005209A
Authority
MX
Mexico
Prior art keywords
sup
compounds
lipid compounds
tautomer
stereoisomer
Prior art date
Application number
MX2025005209A
Other languages
English (en)
Inventor
Matthew Frank Brown
Daniel Paul Canterbury
Ye Che
Wenhua Jiao
Roger Hochoon Pak
Mark Edward Schnute
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2025005209A publication Critical patent/MX2025005209A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/54—Spiro-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se proporcionan compuestos que tienen la siguiente estructura: (Ver compuesto (I)). o una sal farmacéuticamente aceptable, N-óxido, tautómero o estereoisómero del mismo, en donde R1, G1, W y m, n, o y p son como se definen en el presente documento. También se proporciona el uso de los compuestos como componente de formulaciones de nanopartículas lipídicas para la administración de un ácido nucleico, composiciones que comprenden los compuestos y métodos para su uso y preparación.
MX2025005209A 2022-11-04 2025-05-02 Compuestos lipídicos y usos de los mismos MX2025005209A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263382389P 2022-11-04 2022-11-04
US202363590756P 2023-10-16 2023-10-16
PCT/IB2023/061006 WO2024095179A1 (en) 2022-11-04 2023-11-01 Lipid compounds and uses thereof

Publications (1)

Publication Number Publication Date
MX2025005209A true MX2025005209A (es) 2025-06-02

Family

ID=88731299

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2025005209A MX2025005209A (es) 2022-11-04 2025-05-02 Compuestos lipídicos y usos de los mismos

Country Status (7)

Country Link
EP (1) EP4612129A1 (es)
KR (1) KR20250099738A (es)
CN (1) CN120265611A (es)
AU (1) AU2023375183A1 (es)
IL (1) IL320338A (es)
MX (1) MX2025005209A (es)
WO (1) WO2024095179A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025186725A2 (en) 2024-03-06 2025-09-12 Pfizer Inc. Improved lnp formulations and uses thereof
CN119613422B (zh) * 2025-02-12 2025-08-22 北京引正基因科技有限公司 脂质化合物、包含其的组合物及应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197553B1 (en) 1994-07-15 2001-03-06 Merck & Co., Inc. Method for large scale plasmid purification
WO2004002453A1 (en) 2002-06-28 2004-01-08 Protiva Biotherapeutics Ltd. Method and apparatus for producing liposomes
JP5639338B2 (ja) 2005-07-27 2014-12-10 プロチバ バイオセラピューティクス インコーポレイティッド リポソームの製造システムおよび製造方法
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
IL289934B2 (en) 2014-06-25 2023-04-01 Acuitas Therapeutics Inc Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
HUE061564T2 (hu) 2015-10-28 2023-07-28 Acuitas Therapeutics Inc Új lipidek és lipid nanorészecske készítmények nukleinsavak bevitelére
HUE068416T2 (hu) 2019-01-11 2024-12-28 Acuitas Therapeutics Inc Lipidek hatóanyagok lipid nanorészecskék formájában való adagolására
US20230009076A1 (en) 2019-06-28 2023-01-12 Serina Therapeutics, Inc. Polyoxazoline-drug conjugates with novel pharmacokinetic properties
CA3182994A1 (en) * 2020-06-30 2022-01-06 Bo YING Lipid compounds and lipid nanoparticle compositions
BR112023001955A2 (pt) 2020-08-06 2023-04-11 Modernatx Inc Composições para a distribuição de moléculas de carga útil ao epitélio das vias aéreas
CN117043343A (zh) * 2021-07-30 2023-11-10 苏州艾博生物科技有限公司 用于突变型冠状病毒的核酸疫苗

Also Published As

Publication number Publication date
EP4612129A1 (en) 2025-09-10
IL320338A (en) 2025-06-01
AU2023375183A1 (en) 2025-05-01
KR20250099738A (ko) 2025-07-02
CN120265611A (zh) 2025-07-04
WO2024095179A1 (en) 2024-05-10

Similar Documents

Publication Publication Date Title
MX2024007720A (es) Lipidos para la administracion de agentes activos en nanoparticulas lipidicas.
MX2023000614A (es) Lipidos cationicos para usarse en nanoparticulas lipidicas.
WO2023114943A3 (en) Lipids for use in lipid nanoparticle formulations
MX2025005209A (es) Compuestos lipídicos y usos de los mismos
AU2016343803A8 (en) Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2019036008A8 (en) Lipids for use in lipid nanoparticle formulations
EP4420679A3 (en) Lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP4410317A3 (en) Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
WO2021102411A8 (en) Ionizable lipids and nanoparticle compositions thereof
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
EP4501322A3 (en) Lipids for use in lipid nanoparticle formulations
MX2025002671A (es) Lipidos para uso en formulaciones de nanoparticulas de lipidos
WO2002074247A8 (en) Pharmaceutical formulations for sustained release
WO2006067614A3 (en) Heteroaromatic derivatives useful as anticancer agents
SG10201407996PA (en) Lipids, lipid compositions, and methods of using them
WO2023114937A3 (en) Fluorinated cationic lipids for use in lipid nanoparticles
WO2006010574A1 (en) Piperazine derivatives for the treatment of female sexual disorders
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
ZA202403360B (en) Lipid nanoparticles for oligonucleotide delivery
ZA202403337B (en) Lipid nanoparticles for oligonucleotide delivery
ZA202309527B (en) Ionizable lipids and compositions for nucleic acid delivery
ZA202200660B (en) Process for the preparation of ridinilazole and crystalline forms thereof
MX2024003738A (es) Formas solidas, composiciones farmaceuticas y preparacion de compuestos de eter macrociclico heteroaromatico.
MX2021012223A (es) Compuestos de hexahidro-1h-pirazino[1,2-a]pirazina para el tratamiento de una enfermedad autoinmunitaria.
SE0402925D0 (sv) Novel Compounds